Esperion Therapeutics (ESPR) Tops Q3 EPS by 6c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $34 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Morgan Stanley Downgrades Kongsberg Gruppen ASA (KOG:NO) to Underweight